The U.S. companion diagnostics (CDx) development market was valued at USD 412.84 million in 2024, with a projected CAGR of 7.8% expected from 2025 to 2034, reflecting strong contributions from leading countries such as the United States, China, Germany, and Japan. The U.S. remains the global epicenter of CDx innovation, supported by federal funding from agencies such as the National Cancer...